CD33 and acute myeloid leukemia: To test whether Regnase-1 depletion in CAR T-cells could overcome the resistance of TP53-mutant AML cells against CAR T-cells, we knocked out Regnase-1 in CD33-directed as well as CD123-directed CAR T-cells using CRISPR/Cas9 genome editing (Fig. 6F).